215 related articles for article (PubMed ID: 10478243)
41. Increased detection of intracranial metastases with intravenous Gd-DTPA.
Healy ME; Hesselink JR; Press GA; Middleton MS
Radiology; 1987 Dec; 165(3):619-24. PubMed ID: 3317496
[TBL] [Abstract][Full Text] [Related]
42. Irradiation of the cervix uteri: value of unenhanced and contrast-enhanced MR imaging.
Hricak H; Swift PS; Campos Z; Quivey JM; Gildengorin V; Göranson H
Radiology; 1993 Nov; 189(2):381-8. PubMed ID: 8210364
[TBL] [Abstract][Full Text] [Related]
43. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases.
Ba-Ssalamah A; Nöbauer-Huhmann IM; Pinker K; Schibany N; Prokesch R; Mehrain S; Mlynárik V; Fog A; Heimberger K; Trattnig S
Invest Radiol; 2003 Jul; 38(7):415-22. PubMed ID: 12821855
[TBL] [Abstract][Full Text] [Related]
44. Evolution of radiation-induced brain injury: MR imaging-based study.
Wang YX; King AD; Zhou H; Leung SF; Abrigo J; Chan YL; Hu CW; Yeung DK; Ahuja AT
Radiology; 2010 Jan; 254(1):210-8. PubMed ID: 20019142
[TBL] [Abstract][Full Text] [Related]
45. Magnetic resonance imaging of brain metastases: magnetisation transfer or triple dose gadolinium?
Thng CH; Tay KH; Chan LL; Lim EH; Khoo BK; Huin EL; Tan KP
Ann Acad Med Singap; 1999 Jul; 28(4):529-33. PubMed ID: 10561767
[TBL] [Abstract][Full Text] [Related]
46. Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol.
Verry C; Sancey L; Dufort S; Le Duc G; Mendoza C; Lux F; Grand S; Arnaud J; Quesada JL; Villa J; Tillement O; Balosso J
BMJ Open; 2019 Feb; 9(2):e023591. PubMed ID: 30755445
[TBL] [Abstract][Full Text] [Related]
47. Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging.
Young SW; Sidhu MK; Qing F; Muller HH; Neuder M; Zanassi G; Mody TD; Hemmi G; Dow W; Mutch JD
Invest Radiol; 1994 Mar; 29(3):330-8. PubMed ID: 8175308
[TBL] [Abstract][Full Text] [Related]
48. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
[TBL] [Abstract][Full Text] [Related]
49. Imaging of human colon cancer xenograft with gadolinium-texaphyrin.
Young SW; Fan Q
Invest Radiol; 1996 May; 31(5):280-3. PubMed ID: 8724126
[TBL] [Abstract][Full Text] [Related]
50. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases.
Yuh WT; Engelken JD; Muhonen MG; Mayr NA; Fisher DJ; Ehrhardt JC
AJNR Am J Neuroradiol; 1992; 13(1):335-45. PubMed ID: 1595472
[TBL] [Abstract][Full Text] [Related]
51. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.
Kumar AJ; Leeds NE; Fuller GN; Van Tassel P; Maor MH; Sawaya RE; Levin VA
Radiology; 2000 Nov; 217(2):377-84. PubMed ID: 11058631
[TBL] [Abstract][Full Text] [Related]
52. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.
Runge VM; Wells JW; Nelson KL; Linville PM
J Magn Reson Imaging; 1994; 4(5):669-73. PubMed ID: 7981511
[TBL] [Abstract][Full Text] [Related]
53. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
Bradley KA; Pollack IF; Reid JM; Adamson PC; Ames MM; Vezina G; Blaney S; Ivy P; Zhou T; Krailo M; Reaman G; Mehta MP;
Neuro Oncol; 2008 Oct; 10(5):752-8. PubMed ID: 18715950
[TBL] [Abstract][Full Text] [Related]
54. [Use of contrast agent in high-field MRI (3 T)].
Trattnig S; Ba-Ssalamah A; Nöbauer-Huhmann IM; Barth M; Pinker K; Mlynarik V
Radiologe; 2004 Jan; 44(1):56-64. PubMed ID: 14740095
[TBL] [Abstract][Full Text] [Related]
55. Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial.
Kotb S; Detappe A; Lux F; Appaix F; Barbier EL; Tran VL; Plissonneau M; Gehan H; Lefranc F; Rodriguez-Lafrasse C; Verry C; Berbeco R; Tillement O; Sancey L
Theranostics; 2016; 6(3):418-27. PubMed ID: 26909115
[TBL] [Abstract][Full Text] [Related]
56. Immediate hypersensitivity reaction to gadolinium-based MR contrast media.
Jung JW; Kang HR; Kim MH; Lee W; Min KU; Han MH; Cho SH
Radiology; 2012 Aug; 264(2):414-22. PubMed ID: 22550309
[TBL] [Abstract][Full Text] [Related]
57. Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium Administration.
Adin ME; Kleinberg L; Vaidya D; Zan E; Mirbagheri S; Yousem DM
AJNR Am J Neuroradiol; 2015 Oct; 36(10):1859-65. PubMed ID: 26294649
[TBL] [Abstract][Full Text] [Related]
58. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.
Wu GN; Ford JM; Alger JR
J Neurooncol; 2006 Mar; 77(1):95-103. PubMed ID: 16547607
[TBL] [Abstract][Full Text] [Related]
59. Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions.
Mathews VP; Caldemeyer KS; Ulmer JL; Nguyen H; Yuh WT
J Magn Reson Imaging; 1997; 7(1):14-22. PubMed ID: 9039589
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
